PGN-EDO51, an enhanced delivery oligonucleotide (EDO) for the treatment of duchenne muscular dystrophy (DMD): results of a phase 1 study in healthy volunteers (P3-8.004)
The following is a comparison of the incidence rates of gastrointestinal adverse events with semaglutide at different doses from randomized controlled trials: Serious events and warnings: Rare but serious side effects of semaglutide and dulaglutide are: Pancreatitis (inflammation of the pancreas) Changes in vision (worsening diabetic retinopathy) Gallbladder issues (cholecystitis and cholelithiasis) Injection site reactions (redness, inflammation, infection, and scarring) Severe stomachache Suicidal ideation Excessive burping Mood and behaviour changes Hypoglycemia Allergic or hypersensitivity reaction High risk of aspiration (stomach content entering the respiratory tract) during surgical procedures that require anesthesia or sedation GLP-1 medications are contraindicated for patients with a personal or family history of medullary thyroid carcinoma and MEN 2 syndrome (Multiple endocrine neoplasia type 2 syndrome)
Dovetailing counseling or support groups enables patients to digest the changes, set a more reasonable expectation, and consider alternatives with a cooler head instead of rushing to surgery
GHK-Cu is sensitive to pH, light, oxygen and heat
doi:10.1002/lary.25589 Owens RL, Eckert DJ, Yeh SY, Malhotra A
